A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs TRV 027 (Primary)
  • Indications Acute heart failure; Decompensated heart failure
  • Focus Therapeutic Use
  • Acronyms BLAST-AHF
  • Sponsors Trevena
  • Most Recent Events

    • 27 Apr 2017 Results published in the European Heart Journal
    • 27 Apr 2017 Status changed from active, no longer recruiting to completed, according to results published in the European Heart Journal.
    • 20 Oct 2016 This trial has been completed in Bulgaria (end date: 28 Aug 2016), Czech Republic (end date: 28 Aug 2016) and Germany (end date: 28 Aug 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top